Announcements
- Immutep Reports Promising Clinical Data from INSIGHT-003 Trial at ESMO Congress 2023
- Immutep’s Efti in Combination with KEYTRUDA® Generates Excellent Overall Survival Benefit in Patients with Metastatic Non-Small Cell Lung Cancer
- Immutep’s Efti in Combination with Pembrolizumab Achieves Excellent Initial Overall Survival Benefit in 1st Line Non-Small Cell Lung Cancer
- Immutep Receives Approval to Initiate INSIGHT-005 Trial Evaluating Eftilagimod Alpha and Anti-PD-L1 Therapy BAVENCIO®
Key statistics
As of last trade, Immutep Ltd (IMMP:NMQ) traded at 2.26, 50.67% above the 52 week low of 1.50 set on May 15, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.20 |
---|---|
High | 2.32 |
Low | 2.20 |
Bid | 2.22 |
Offer | 2.24 |
Previous close | 2.20 |
Average volume | 191.51k |
---|---|
Shares outstanding | -- |
Free float | -- |
P/E (TTM) | -- |
Market cap | -- |
EPS (TTM) | -- |
Data delayed at least 15 minutes, as of Apr 19 2024 14:37 BST.
More ▼